Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
bispecific antibodies
Biotech
Takeda shoots down bispecifics bagged in Maverick buyout
The two bispecific terminations, coupled to the removal of a third asset, halved the number of cancer candidates in Takeda’s phase 1 and 2 pipeline.
Nick Paul Taylor
May 8, 2025 8:30am
Stealth biotech bags rights to VelaVigo bispecific in $440M deal
Apr 18, 2025 7:40am
Sanofi pens $1.8B deal for 2 autoimmune, immunology bispecifics
Apr 17, 2025 8:51am
NAYA spins off cancer drug business 6 months after INVO merger
Apr 15, 2025 8:05am
ADCs to cell therapy: How AZ aims to 'redefine' oncology
Apr 9, 2025 11:44am
F-star breaks free from invoX after $161M acquisition
Apr 4, 2025 10:03am
